Abstract:Alessandra Morano, 1 Martina Fanella, 1 Mariarita Albini, 1 Pierangelo Cifelli, 2, 3 Eleonora Palma, 2 Anna Teresa Giallonardo, 1 Carlo Di Bonaventura 1 1 Epilepsy Unit, Department of Human Neurosciences, "Sapienza" University of Rome, Rome, Italy; 2 Department of Physiology and Pharmacology, Pasteur Institute-Cenci Bolognetti Foundation, University of Rome Sapienza, Rome, Italy; 3 IRCCS "Neuromed", Pozzilli, IS, Italy Correspondence: Carlo Di Bonaventura Epilepsy Unit, Department of Human Neurosciences, "Sapienza" University of Rome, P.le A. Moro, 5, Rome 00185, Italy Email c_dibonaventura@yahoo.it Cannabidiol (CBD) is one of the prominent phytocannabinoids found in Cannabis sativa , differentiating from Δ 9 -tetrahydrocannabinol (THC) for its non-intoxicating profile and its antianxiety/antipsychotic effects. CBD is a multi-target drug whose anti-convulsant properties are supposed to be independent of endocannabinoid receptor CB 1 and might be related to several underlying mechanisms, such as antagonism on the orphan GPR55 receptor, regulation of adenosine tone, activation of 5HT 1A receptors and modulation of calcium intracellular levels. CBD is a lipophilic compound with low oral bioavailability (6%) due to poor intestinal absorption and high first-pass metabolism. Its exposure parameters are greatly influenced by feeding status (ie, high fat-containing meals). It is mainly metabolized by cytochrome P 450 (CYP) 3A4 and 2C19, which it strongly inhibits. A proprietary formulation of highly purified, plant-derived CBD has been recently licensed as an adjunctive treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), while it is being currently investigated in tuberous sclerosis complex. The regulatory agencies' approval was granted based on four pivotal double-blind, placebo-controlled, randomized clinical trials (RCTs) on overall 154 DS patients and 396 LGS ones, receiving CBD 10 or 20 mg/kg/day BID as active treatment. The primary endpoint (reduction in monthly seizure frequency) was met by both CBD doses. Most patients reported adverse events (AEs), generally from mild to moderate and transient, which mainly consisted of somnolence, sedation, decreased appetite, diarrhea and elevation in aminotransferase levels, the last being documented only in subjects on concomitant valproate therapy. The interaction between CBD and clobazam, likely due to CYP2C19 inhibition, might contribute to some AEs, especially somnolence, but also to CBD clinical effectiveness. Cannabidivarin (CBDV), the propyl analogue of CBD, showed anti-convulsant properties in pre-clinical studies, but a plant-derived, purified proprietary formulation of CBDV recently failed the Phase II RCT in patients with uncontrolled focal seizures. Keywords: cannabidiol, cannabidivarin, phytocannabinoids, epileptic encephalopathies, tuberous sclerosis complex, drug-resistance

A Review with Focus on CDKL5 Deficiency Disorder

CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment

Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5R59X knock‐in mice

Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database

Therapeutic advances in Dravet syndrome: a targeted literature review

Novel CDKL5 targets identified in human iPSC-derived neurons

Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects

Cannabidiol Treatment for Refractory Epilepsies in Pediatrics

Advancements in Dravet Syndrome Therapeutics: A Comprehensive Look at Present and Future Treatment Horizons: A Focused Review

An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder

Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

Focal cortical dysplasia as a cause of epilepsy: The current evidence of associated genes and future therapeutic treatments

Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies

Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy

Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects

CBD in the Treatment of Epilepsy

Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder

Cannabis, More Than the Euphoria: Its Therapeutic Use in Drug-Resistant Epilepsy

Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations

Neuronal hyperexcitability and ion channel dysfunction in CDKL5-deficiency patient iPSC-derived cortical organoids

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders